Omega3 Supplementation in the Prevention of Contrast Induced Nephropathy in Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized PlaceboControlled Trial

Purpose: Contrastinduced nephropathy (CIN) is the third cause of hospitalacquired renal failure and is associated with significant morbidity and mortality. Several studies have revealed the protective role of omega3 in prevention and treatment of some kidney injuries. This study was conducted to examine the effect of omega3 supplementation on the markers of renal function and to evaluate its potential in the prevention of CIN in patients undergoing elective percutaneous coronary intervention (PCI). Methods: In this doubleblind, randomized clinical trial, 85 eligible patients scheduled for PCI was randomly divided into omega3 (a single 3750 mg dose of omega3 as well as routine hydration therapy within 12 hours before PCI) or control (placebo plus routine hydration therapy) groups. Serum creatinine (SCr) and cystatin C levels were measured at baseline and 24 hours after PCI. Results: Our results indicated that post PCI cystatin C levels were significantly decreased in the omega3 group compared to the control group (P lt; 0.001). Although less upward manner was seen in the level of 24hour creatinine in the omega3 group, it did not reach the significance level (P = 0.008). Conclusion: The positive effect of omega3 on cystatin C levels showed that it may have a protective role in the prevention of CIN in postPCI patients with normal kidney function. However, to better assess this effect, it is highly recommended to design future studies with higher doses and longer duration of therapy with omega3 plus longterm follow up.